A cancer vaccine developed by Moderna Inc. and Merck & Co. Inc. showed promising results in a key study, reducing the risk of recurrence or death by 44%.
A cancer vaccine developed by Moderna Inc. and Merck & Co. Inc. showed promising results in a key study, reducing the risk of recurrence or death by 44%, the drug makers said Sunday.
About 79% of melanoma patients in a 157-person trial who were treated with Moderna’s personalized mRNA-4157 therapy in combination with Merck’s cancer drug Keytruda were cancer-free after 18 months, compared with 62% of patients who received only Keytruda, “a statistically significant and clinically meaningful improvement ” the companies... A cancer vaccine developed by Moderna Inc. and Merck & Co. Inc.
About 79% of melanoma patients in a 157-person trial who were treated with Moderna’s personalized mRNA-4157 therapy in combination with Merck’s cancer drug Keytruda were cancer-free after 18 months, compared with 62% of patients who received only Keytruda, “a statistically significant and clinically meaningful improvement ” the companies said in a joint statement Sunday.
The combination treatment has been designated by the U.S. Food and Drug Administration and European Medicines Agency as a breakthrough therapy, and additional data about the study will be released at an upcoming medical meeting and published in a pee-reviewed publication, the companies said. Merck shares MRK are up 3.9% year to date, and up 33% over the past year. Moderna shares MRNA are down 12.5% in 2023 and down 5% over the past 12 months.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Moderna cancer vaccine with Merck's Keytruda delays return of deadly skin cancerAn experimental mRNA vaccine developed by Moderna Inc combined with Merck & Co's blockbuster immunotherapy Keytruda cut the risk of death or recurrence of the most deadly skin cancer by 44% compared Keytruda alone, U.S. researchers reported at a medical meeting on Sunday.
Read more »
Moderna cancer vaccine with Merck's Keytruda delays return of deadly skin cancerModerna cancer vaccine with Merck’s Keytruda delays return of deadly skin cancer
Read more »
Moderna/Merck cancer vaccine plus Keytruda delays skin cancer returnAn experimental mRNA cancer vaccine developed by Moderna Inc and Merck & Co cut the risk of death or recurrence of the most deadly skin cancer by 44% compared with Merck's immunotherapy Keytruda alone, U.S. researchers reported at a medical meeting on Sunday.
Read more »
Moderna, Merck Show Progress Toward Cancer VaccinesModerna’s mRNA cancer vaccine helped prevent relapse for people with high-risk melanoma in a mid-stage trial, some of the strongest evidence yet that such vaccines could benefit patients
Read more »
Merck to buy Prometheus Biosciences for $10.8 billionMerck & Co. Inc. announced Sunday a deal to acquire Prometheus Biosciences Inc. for $200 a share, or about $10.8 billion.
Read more »